Expressed mutated genes in Sezary syndrome and their potential prognostic value in patients treated with extracorporeal photopheresis

This is the first evaluation in SS of expressed mutations in a large panel of CTCL-driver genes. Also innovative is the monitoring of mutated genes in patients' malignant lymphocytes during ECP, a first-line treatment of CTCL, which highlights novel candidates associated with ECP resistance that might unmask novel pharmacological vulnerabilities to be exploited during ECP for a personalized treatment.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2025-08-22
DOI
https://doi.org/10.3389/fimmu.2025.1589467
Citations
1
Primary Topic
Cutaneous lymphoproliferative disorders research
Type
article
Field-Weighted Citation Impact
2.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Expressed mutated genes in Sezary syndrome and their potential prognostic value in patients treated with extracorporeal photopheresis

Cristina Cristofoletti, Cristian Bassi, Maria Pilla, Alessandra Frezzolini et al.
1 citations
Frontiers in Immunology
Cutaneous lymphoproliferative disorders research
2.00
article

Expressed mutated genes in Sezary syndrome and their potential prognostic value in patients treated with extracorporeal photopheresis

Cristina Cristofoletti, Cristian Bassi, Maria Pilla, Alessandra Frezzolini, Martina Fioretti, Alessandro Monopoli, Cosimo Di Raimondo, Luca Mazzarella, Gianmaria Frigè, Ylenia Aura Minafò, Giandomenico Russo, Giulia Salvatore, Stefania D’Atri, Maria Grazia Narducci, Enrico Scala, Maria Pina Accetturi, Massimo Negrini, Giovanni Luca Scaglione
article en
1 citations

Abstract

This is the first evaluation in SS of expressed mutations in a large panel of CTCL-driver genes. Also innovative is the monitoring of mutated genes in patients' malignant lymphocytes during ECP, a first-line treatment of CTCL, which highlights novel candidates associated with ECP resistance that might unmask novel pharmacological vulnerabilities to be exploited during ECP for a personalized treatment.

Frontiers in ImmunologyVol. 16
University of Ferrara (IT), Istituto Dermopatico dell'Immacolata (IT), Policlinico Tor Vergata (IT), European Institute of Oncology (IT)
Ministero della Salute
Openalex Percentile: Top 12%
Cutaneous lymphoproliferative disorders research
2.00
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.